{"page":{"totalFilteredElements":36},"studies":[{"active":true,"description":"Lenalidomide, Adriamycin, Dexamethasone \n(RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction\n in Newly Diagnosed Multiple Myeloma Followed by Response-adapted \nConsolidation and Lenalidomide Maintance &#8211; A Randomized Multicenter \nPhase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)","eudractNumber":"2009-016616-21","id":414,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT01685814","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2012-07-20T12:37:36+02:00","shortTitle":"DSMM XIV","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<b>GMMG HD9/ DSMM XVIII:</b> A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.","eudractNumber":"2023-507402-13","id":9091,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06216158","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-04-03T13:12:13+02:00","shortTitle":"DSMM XVIII [GMMG HD9]","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with</div><div>Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as</div><div>Induction Therapy and Teclistamab in Combination with Daratumumab and</div><div>Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma</div><div><br /></div>","eudractNumber":"2022-001186-12","id":8497,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05695508","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-12-01T15:24:49+01:00","shortTitle":"DSMM XX [GMMG-HD10], MajesTEC-5","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/ bortezomib/ dexamethasone (I-VRD) followd by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followd standard of care intensification followed by maintenance therapy with lenalidomide and isatuximab<div><br /></div><div>Short title: Expression-linked and R-Iss-Adapted Stratification for first line therapy in multiple myeloma patients (ELIAS)</div>","eudractNumber":"2020-005102-26","id":9532,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05665140","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-07-01T12:46:18+02:00","shortTitle":"ELIAS","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued</div><div>Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients</div>","eudractNumber":"2024-519827-16-00","id":11504,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06932562","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-11-10T09:57:13+01:00","shortTitle":"EMN 39","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga<br />","eudractNumber":null,"id":6546,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-04-01T11:55:14+02:00","shortTitle":"GAM-36","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-Interventionelle Studie (NIS) zum klinischen Einsatz von Octagam 5%, Octagam 10% oder panzyga<br />","eudractNumber":null,"id":11341,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-01-28T09:00:35+01:00","shortTitle":"GAM-36","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Long-Term Follow up Protocol for subjects treated with gene-modified T Cells<br />","eudractNumber":"2017-001465-24","id":5382,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT03435796","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2019-01-10T13:02:46+01:00","shortTitle":"GC-LTFU-001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Gustabor Phase 1 &#8211; KI-basierte Erstellung eines Ern&#228;hrungsplans zum Ausgleich von Chemotherapie-bedingten Geschmacksst&#246;rungen","eudractNumber":null,"id":11060,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"gio4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"giu4","name":"Weitere Tumoren des Verdauungstraktes (z.B. Gastrointestinale Stromatumoren, GIST)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"}],"mutations":[],"nctNumber":"NCT07040189","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-11-25T10:41:56+01:00","shortTitle":"Gustabor1","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/ or refractory multiple myeloma (RRMM) according to the approved label<br /><div><br /></div><div>DRKS00033264</div>","eudractNumber":null,"id":9047,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-05-16T14:39:00+02:00","shortTitle":"HARBOUR","therapeutical":false,"therapyLines":[]}]}